ArticleInternal medicine (Tokyo, Japan)2025
Significance of Serum Cholinesterase as a Prognostic Marker in Patients with Non-dialysis-dependent Chronic Kidney Disease.
Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Electrochemical Biosensor-Based Evaluation of Cholinergic Biomarkers in Experimental Nephropathy.Analytical chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective Malnutrition is a common problem among patients with chronic kidney disease (CKD). It is unknown whether serum cholinesterase, an indicator of the nutritional status, has a significant value as a prognostic marker in patients with non-dialysis-dependent CKD, including those in the early phase. Methods A total of 4,505 middle-aged and older people with stage 1-4 CKD who were free from cardiovascular events (mean age: 67.2 years) were followed up for an average of 10.3±2.4 years. We investigated the association of serum cholinesterase levels with all-cause mortality using multivariable regression analyses and restricted cubic spline analyses. Results A total of 840 (18.6%) participants died. The multivariable-adjusted hazard ratios (HRs) for all-cause mortality were significantly increased in patients with serum cholinesterase in the first and second quartiles compared to patients in the highest quartile in the entire cohort [HR=1.61, 95% confidence interval (CI), 1.28-2.03; HR=1.37, 95% CI, 1.09-1.71, respectively]. A reverse-J relationship between the serum cholinesterase levels and all-cause mortality was found in the entire cohort as well as in patients grouped according to stage 1-2 CKD and stage 3-4 CKD (all p for nonlinearity: <0.030). The inclusion of the serum cholinesterase level improved the accuracy of reclassification in a conventional prediction model for 10-year all-cause mortality (continuous net reclassification improvement=0.167, p<0.001; integrated discrimination improvement=0.005, p<0.001). Conclusion In middle-aged and older people with stage 1-4 CKD, the serum cholinesterase level had significant value in predicting all-cause mortality and added prognostic information to conventional risk assessments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.